Las drogas Inhibidoras de los Puntos de Control Inmunológico para tratamiento del cáncer. Un Nuevo reto para la Onco-Reumatología de Cuba
Keywords:
drogas Inhibidoras de los Puntos de Control Inmunológico, tratamiento del cáncer, Onco-Reumatología de CubaAbstract
En los últimos años se ha ido desarrollando una nueva disciplina médica denominada Onco-Reumatología. Está considerada un punto de unión entre la Oncología y la Reumatología, basada en los resultados de las investigaciones acerca de los complejos mecanismos patogénicos, aspectos clínicos y estrategias terapéuticas que involucran a los pacientes con enfermedades autoimmune reumáticas y procesos tumorales malignos
Downloads
References
Zoltán Szekanecza, Izabella Gomeza,g, Boglárka Soósa, Levente Bodokia, Szilvia Szamosia, Csilla Andrásd, Balázs Juhászd, László Váróczyb, Péter Antal-Szalmáse, Péter Szodorayc,j, Nóra Bittnerf et al. Eight pillars of Oncorheumatology: Cross-roads between malignancies and musculoskeletal diseases. Autoimmunity Review,19 (2020):102658.
Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev 2017;16:1049–57.
Ami A. Shah, Livia Casciola-Rosen, and Antony Rosen. Cancer-Induced Autoimmunity in the Rheumatic Diseases. Review. Arthritis & Rheumatology. Vol. 67, No. 2, February 2015, pp 317–326 DOI 10.1002/art.38928 © 2015 .
Carl Turesson and Eric L. Matteson. Review Malignancy as a comorbidity in rheumatic diseases. Rheumatology 2013;52:514. rheumatology/kes.
Klavdianou K, Melissaropoulos K, Filippopoulou A, Daoussis D. Should we be Afraid of Immune Check Point Inhibitors in Cancer patients with Pre-existing Rheumatic Diseases?. Mediterr J Rheumatol 2021;32(3):218-26.
Cutolo M, Paolino S, Pizzorni C. Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol 2014;32:839–47.
Saya Jacob, MD; Kian Rahbari, BS; Kyle Tegtmeyer, BS; Jeffrey Zhao, BA; Steven Tran, BS; Irene Helenowski, PhD; Hui Zhang, PhD; Theresa Walunas; John Varga; Jane Dematte; Victoria Villaflor. Oncology Lung Cancer Survival in Patients With Autoimmune Disease. JAMA Network Open. 2020;3(12):e2029917. doi:10.1001/jamanetworkopen.2020.29917
Jian Wen, Han Ouyang, Ru Yang, Lin Bo, Yi Zhang, Mei Tang & Zhichun Liu; Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis Scientif Report. (2018) 8:1786 | DOI:10.1038/s41598-018-20167
Kaitlin R McCarter, Senada Arabelovic, Xiaosong Wang, Taylor Wolfgang, Kazuki Yoshida , Grace Qian , Emily N Kowalski , Kathleen M M Vanni, Nicole R LeBoeuf , Elizabeth I Buchbinder , Lydia Gedmintas, Lindsey A MacFarlane, Deepak A Rao , Nancy A Shadick, Ellen M Gravallese, Jeffrey A Sparks. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune check point inhibitors for cancer. Semin arthritis reum. 2024 Feb:64:152335. doi: 10.1016/j.semarthrit.2023.1
Berna C. Özdemir · Cristina Espinosa da Silva · Dimitri Arangalage · Pierre Monney · Sabina A. Guler · Uyen Huynh Do · Guido Stirnimann · et.al.,Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune related adverse events among cancer patients. .Cancer Immunology, Immunotherapy (2023) 72:1991–2001 https://doi.org/10.1007/s00262-023-03436-0
Menglu Pan , Huanhuan Zhao , Ruimin Jin , Patrick S. C. Leung and Zongwen Shuai. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future. Frontiers in Inmunology. Review Published 06 April 2023. DOI 10.3389/fimmu.2023.1156212
Konstantinos Melissaropoulos , Kalliopi Klavdianou, Alexandra Filippopoulou Fotini Kalofonou, Haralabos Kalofonos and Dimitrios Daoussis. Review. Rheumatic Manifestations in patients treated with Immune Checkpoint Inhibitors. Int. J. Mol. Sci. 2020, 21, 3389; doi:10.3390/ijms21093389 www.mdpi.com/journal/ijms
Laura C. Capelli, Julie R. Bhramer, Patrick M. Forde, Dun T Le, Evan J lipson Jarushka Jainodo, Lei Zheng, Clifton O. Bigham, Ami A. Shad, Lei Zheng. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Seminars in Arthritis and Rheumatism. Volume 48, Issue 3, December 2018, Pages 553-557.
Li Zeng Gang Ma, Kai Chen and Qiao Zhou Zeng L, Ma G, Chen K and Zhou Q (2023). Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors. Front. Immunol. 14:1242336. doi: 10.3389/fimmu.2023.1242336
Amanda Lusa, Carolina Alvarez, Shruti Saxena Beem, Todd A. Schwartz and Rumey Ishizawar. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy. BMC Rheumatology (2022) 6:64 https://doi.org/10.1186 /s41927-022-00297-5
Szekanecza Z. autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment, hung. Medizinhist J 2019;160:887–95.
Maria Cecilia Garbarino, Natalia Manzano, Osvaldo Messina, Marcelo Zylberman. Rheumatological adverse events secondary to immune checkpoint inhibitors Reumatología Clínica vol 119, 4 (2023): 215-222. https://doi.org /10.1016/ j.reuma.2022.09.004
Si-Yang Liu, Yi-Long Wu. An immunological storm for cancer therapy: 2018 Nobel Prize in Physiology or Medicine. Science Bulletin 63 (2018) 1608–1610 https://doi.org/10.1016/j.scib.2018.11.023 2095-9273/
Anne Madroszyk. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. Joint Bone Spine. Volume 90, Issue 1, January 2023, 105457. https://doi.org/10.1016/j.jbspin.2022.105457
Gil Alberto Reyes Llerena. Editorial. El reto del internista ante las enfermedades autoinmune reumáticas . The Challenge Faced by Internists in Rheumatological Autoimmune Diseases, Revista Cubana de Medicina. 2023 (Oct-Dic); 62(4):e3478. https://orcid.org/0000-0001-7749-5652
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
